Organic Pressurized Fluid Patents (Class 424/45)
-
Patent number: 9533053Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.Type: GrantFiled: June 13, 2014Date of Patent: January 3, 2017Assignee: Alcon Research, Ltd.Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
-
Patent number: 9517204Abstract: The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.Type: GrantFiled: September 13, 2012Date of Patent: December 13, 2016Assignees: SHIONOGI & CO., LTD., SHIZUOKA PREFECTURAL UNIVERSITIES CORPORATIONInventors: Satomi Onoue, Shizuo Yamada
-
Patent number: 9511144Abstract: A cosmetic composition suitable for topical application is provided. In some examples, the cosmetic composition can include glycerin, hexyldecanol, a vitamin B compound, and one or more materials selected from the group consisting of 1,2-pentanediol, 1,4-pentanediol, 2,4-pentanediol, 1,5-pentanediol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, 1,2-hexanediol, 1,5-hexanediol, 1,6-hexanediol, 2,5-hexanediol, hexylene glycol, and combinations thereof.Type: GrantFiled: March 14, 2013Date of Patent: December 6, 2016Assignee: The Proctor & Gamble CompanyInventors: Stevan David Jones, Kunal Virendra Gujraty, Naohisa Yoshimi, Monalisha Paul, James Terence Wescott
-
Patent number: 9486394Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.Type: GrantFiled: October 14, 2013Date of Patent: November 8, 2016Assignee: STIEFEL WEST COAST, LLCInventors: Albert Zorko Abram, Lilian Fuchshuber
-
Patent number: 9474729Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.Type: GrantFiled: January 14, 2011Date of Patent: October 25, 2016Assignee: HYDROMER, INC.Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening
-
Patent number: 9468590Abstract: The invention relates to a foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (M1) and at least one further monomer.Type: GrantFiled: December 10, 2010Date of Patent: October 18, 2016Assignee: NEUBOURG SKIN CARE GMBH & CO. KGInventor: Rolf Daniels
-
Patent number: 9456978Abstract: The present invention is directed towards a composition comprising, in a cosmetically acceptable carrier, at least one silicone-organic polymer hybrid compound; at least one nonionic film forming polymer; at least one amphoteric film forming polymer; and a neutralizer. The present invention also relates to methods for imparting shape to or maintaining the shape of hair wherein the composition provides style memory, strong hold and good shine, while at the same time, providing smoothness and a natural feel to the hair.Type: GrantFiled: December 28, 2012Date of Patent: October 4, 2016Assignee: L'OREALInventors: Aziza Suleiman, Clarissa Nogueira
-
Patent number: 9452173Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: GrantFiled: January 31, 2014Date of Patent: September 27, 2016Assignee: MERZ PHARMACEUTICALS, LLCInventors: Bhushan Hardas, Donna Dalton, Petra Scheppler, Anja Buch, Peter Boderke
-
Patent number: 9446131Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: GrantFiled: December 18, 2015Date of Patent: September 20, 2016Assignee: MERZ PHARMACEUTICALS, LLCInventors: Bhushan Hardas, Donna Dalton, Petra Scheppler, Anja Buch, Peter Boderke
-
Patent number: 9447027Abstract: This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.Type: GrantFiled: October 20, 2011Date of Patent: September 20, 2016Assignee: The General Hospital CorporationInventors: David J. Milan, David S. Peal
-
Patent number: 9421166Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.Type: GrantFiled: April 8, 2014Date of Patent: August 23, 2016Assignee: Novartis AGInventors: Thomas E Tarara, Jeffry G Weers, Maria Geraldine Venthoye
-
Patent number: 9422327Abstract: The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.Type: GrantFiled: March 26, 2004Date of Patent: August 23, 2016Assignee: TAKEDA GMBHInventor: Beate Schmidt
-
Patent number: 9402932Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.Type: GrantFiled: September 9, 2014Date of Patent: August 2, 2016Assignee: Poly-Med, Inc.Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
-
Patent number: 9404927Abstract: Embodiments of the invention provide a method detecting and treating cancer, such as lung cancer. In some aspects, the method may include detecting cancer in a subject, which may comprise assessing the expression of a marker in a sample from the subject. For example, the marker may comprise c-Met and/or Fn14. In some embodiments, if the subject is diagnosed as having cancer, the method may further provide administering a therapeutically effective amount of a substance that reduces the expression level of Fn14 to the subject to reduce the invasive and migratory capabilities of the cancer.Type: GrantFiled: December 5, 2014Date of Patent: August 2, 2016Assignee: The Translational Genomics Research InstituteInventors: Timothy G. Whitsett, Nhan L. Tran
-
Patent number: 9382362Abstract: A process for manufacturing a fluoropolymer hybrid organic/inorganic composite comprising: (i) mixing at least one fluoropolymer comprising recurring units derived from at least one (meth)acrylic monomer [monomer (MA)] of formula: at least one metal compound [compound (M)] of formula: X4-mAYm, wherein each of R1, R2, R3, equal or different from each other, is independently a hydrogen atom or a C1-C3 hydrocarbon group, and ROH is a hydrogen atom or a C1-C5 hydrocarbon moiety comprising at least one hydroxyl group [polymer (F)]; wherein m is an integer from 1 to 4, A is a metal selected from the group consisting of Si, Ti and Zr, Y is a hydrolysable group, X is a hydrocarbon group comprising one or more functional groups; (ii) reacting at least a fraction of hydroxyl groups of the ROH groups of said monomer (MA) of said polymer (F) with at least a fraction of said compound (M), to obtain a grafted polymer comprising pendant —Ym-1AX4-m groups, with m, Y, A and X having same meaning as above; and (iii) hyType: GrantFiled: March 31, 2011Date of Patent: July 5, 2016Assignee: SOLVAY SPECIALTY POLYMERS ITALY S.PA.Inventors: Julio A. Abusleme, Riccardo Pieri, Ivan Pagin
-
Patent number: 9370487Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.Type: GrantFiled: July 18, 2014Date of Patent: June 21, 2016Assignee: Precision Dermatology, Inc.Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
-
Patent number: 9351922Abstract: The present invention relates to a composition that provides for skin pigment correction comprising: zinc oxide; octinoxate; ?-arbutin; ascorbic acid; glycyrrhiza glabra extract; green tea extract; pomegranate extract; cucumber extract; niacinamide; and a carrier. The composition can be used to treat a variety of pigment issues including lentigo, liver spots, melasma, post-inflammatory pigment issues, sun spots, freckles, and age spots.Type: GrantFiled: February 21, 2014Date of Patent: May 31, 2016Inventor: Thomas Christopher Balshi
-
Patent number: 9345666Abstract: A foamable pharmaceutical composition and a method of treating corticosteroid-responsive dermatoses of the skin are disclosed. The foamable pharmaceutical composition comprises a corticosteroid compound as an active ingredient; a quick-break foaming agent including an aliphatic alcohol, water, a fatty alcohol and a surface active agent; a buffering agent; and a propellant. The foamable composition is disposed within a pressurizable container that comprises an aerosol valve assembly including a dip tube communicating with a valve orifice through which the foamable composition is dispensed and an actuator to start and stop dispensation. The valve assembly dispenses a conically-shaped spray at a rate of about 2 to about 0.3 g/sec and provides a foam having a density of about 0.12 to about 0.25 when sprayed at a distance of about 5 to about 10 cm from the valve orifice onto a glass surface that is at ambient room temperature.Type: GrantFiled: June 23, 2015Date of Patent: May 24, 2016Assignee: Delcor Asset CorporationInventors: Michael V. Lowenborg, Kuljit Bhatia
-
Patent number: 9345663Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: April 30, 2014Date of Patent: May 24, 2016Assignee: Gilead Sciences, Inc.Inventor: Alan B. Montgomery
-
Patent number: 9339463Abstract: Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10? or less than or equal to 20? are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.Type: GrantFiled: December 5, 2008Date of Patent: May 17, 2016Inventors: Michael Zamloot, Cherng-chyi Fu, De-Hwa Chao, Andrei Blasko, Su Il Yum
-
Patent number: 9326929Abstract: A non-pressurized container that contains one or more of: a foamable composition of minoxidil, or a pharmaceutically acceptable salt thereof, and a dihydrotestosterone blocker in a formulation with a precise density and viscosity to yield a foam with a temperature sensitivity and shear strength designed for inverted application and immediate targeted release at body temperature under a minimal hand applied pressure to the scalp.Type: GrantFiled: January 6, 2016Date of Patent: May 3, 2016Inventor: Nyangenya Maniga
-
Patent number: 9308162Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.Type: GrantFiled: June 3, 2009Date of Patent: April 12, 2016Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Norton
-
Patent number: 9308208Abstract: A method and device are provided to generate an aerosol having a desired particle sizes, i.e., from molecular to about 10 microns, which can be used to effectively deliver a physiologically active compound to organs and tissues such as the lung, eye, mucosa and skin. The aerosol is formed through vaporization of the compound while mixing the resulting vapor with a gas, in a ratio, to form the desired particle size when a stable concentration of particles in the gas is reached.Type: GrantFiled: July 30, 2010Date of Patent: April 12, 2016Assignee: ALEXZA PHARMACEUTICALS, INC.Inventors: Martin J. Wensley, Daniel Mufson, Craig C. Hodges, Peter M. Lloyd, Daniel D. Rogers
-
Patent number: 9301930Abstract: A refreshment towel with applied solution is an apparatus consisting of a carrying agent, most likely a high quality cotton towel or towelette, that has been saturated with an aqueous solution comprised of various ingredients. The resulting saturated towel can be rubbed on a user's skin such that the aqueous solution that has been absorbed by the towel is transferred. The aqueous solution is compounded specifically to provide cooling, insect repellant, sun protection, freshness, cleansing and other uses. More specifically, the aqueous solution is specially formulated so that desired sensory results take place when the towel comes in contact with the skin.Type: GrantFiled: May 1, 2013Date of Patent: April 5, 2016Inventors: A Jeffrey Whitmire, Mona L Whitmire
-
Patent number: 9295644Abstract: The present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixture (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and (b) a second active ingredient which is budesonide; for the manufacture of a medicament for use in the prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma. The invention further relates to a method for prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma by administering, by inhalation, a composition comprising the first and second active ingredients as defined previously.Type: GrantFiled: September 19, 2003Date of Patent: March 29, 2016Assignee: AstraZeneca ABInventor: Tommy Ekström
-
Patent number: 9295645Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: GrantFiled: June 6, 2011Date of Patent: March 29, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 9283219Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.Type: GrantFiled: September 5, 2014Date of Patent: March 15, 2016Assignee: Cynapsus Therapeutics, Inc.Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
-
Patent number: 9265726Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.Type: GrantFiled: May 12, 2014Date of Patent: February 23, 2016Assignee: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Albert Zorko Abram, Lilian Fuchshuber
-
Patent number: 9265727Abstract: A foamable pharmaceutical composition and a method of treating corticosteroid-responsive dermatoses of the skin are disclosed. The foamable pharmaceutical composition comprises a corticosteroid compound as an active ingredient; a quick-break foaming agent including an aliphatic alcohol, water, a fatty alcohol and a surface active agent; a buffering agent; and a propellant. The foamable composition is disposed within a pressurizable container that comprises an aerosol valve assembly including a dip tube communicating with a valve orifice through which the foamable composition is dispensed and an actuator to start and stop dispensation. The valve assembly dispenses a conically-shaped spray at a rate of about 2 to about 0.3 g/sec and provides a foam having a density of about 0.12 to about 0.25 when sprayed at a distance of about 5 to about 10 cm from the valve orifice onto a glass surface that is at ambient room temperature.Type: GrantFiled: January 14, 2015Date of Patent: February 23, 2016Assignee: DELCOR ASSET CORPORATIONInventors: Michael V. Lowenborg, Kuljit Bhatia
-
Patent number: 9265721Abstract: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a “virtual injection” of the active ingredient to be delivered transdermally without general systemic uptake.Type: GrantFiled: January 23, 2007Date of Patent: February 23, 2016Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Francis Davis
-
Patent number: 9259266Abstract: An apparatus and method for use in sterilizing a surgical instrument is provided. The apparatus includes a surgical instrument that includes a housing having a shaft extending therefrom. The shaft includes one or more grooves defined therein that extends at least partially along the length thereof. The one or more grooves is configured to allow a sterilant passage therethrough. The apparatus also includes a jacket that encloses the shaft and allows the sterilant to travel along the one or more grooves.Type: GrantFiled: January 7, 2014Date of Patent: February 16, 2016Assignee: Covidien LPInventors: Dale F. Schmaltz, Victor K. Appel, Paul Guerra
-
Patent number: 9241876Abstract: The preparation method includes the following steps: dissolving aripiprazole in an acidic solution having an acidifier so as to obtain a medicament having acidic solution; then, performing a wet granulation on or preparing a suspension with the obtained medicament having acidic solution, an alkalizer, and an excipient so as to obtain the aripiprazole medicament formulation; the excipient comprising an antioxidant. The aripiprazole medicament formulation obtained through the preparation method has a significantly reduced amount of related substances, great solubility, great stability, high bioavailability, reduced individual differences, and enhanced wettability and content uniformity of insoluble medicaments.Type: GrantFiled: June 26, 2012Date of Patent: January 26, 2016Assignee: SHANGHAI ZHONGXI PHARMACEUTICAL CORPORATIONInventors: Siji Zheng, Xiaoyi Liu, Linyong Fu, Bo Tan, Min Zhou
-
Patent number: 9226509Abstract: The present invention relates to the use of R—OH alcohols as phagodeterrents, and to a method for treating plants infested with aphids which comprises the administration of these R—OH alcohols.Type: GrantFiled: May 14, 2012Date of Patent: January 5, 2016Assignee: Consiglio Nazionale Delle RicercheInventors: Maria Agnese Sabatini, Sonia Ganassi, Claudio Altomare, Mara Favilla, Antonio Evidente, Anna Andolfi
-
Patent number: 9220717Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.Type: GrantFiled: March 2, 2010Date of Patent: December 29, 2015Inventor: Doris Hexsel
-
Patent number: 9205100Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene.Type: GrantFiled: March 1, 2012Date of Patent: December 8, 2015Assignees: Quark Pharmaceuticals, Inc., Washington UniversityInventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
-
Patent number: 9199870Abstract: A high-surface quality glass sheet is formed using a roll-to-roll glass soot deposition and sintering process. The glass sheet formation involves providing glass soot particles, depositing a first fraction of the glass soot particles on a deposition surface to form a supported soot layer, electrostatically attracting and collecting a second fraction of the glass soot particles onto a surface of a charged plate, removing the soot layer from the deposition surface to form a soot sheet, and heating at least a portion of the soot sheet to sinter the glass soot particles to form a glass sheet.Type: GrantFiled: May 22, 2012Date of Patent: December 1, 2015Assignee: CORNING INCORPORATEDInventors: Daniel Warren Hawtof, Brenton Allen Noll, Srinivas Vemury
-
Patent number: 9192654Abstract: The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.Type: GrantFiled: July 11, 2011Date of Patent: November 24, 2015Assignee: CLL PHARMAInventors: Jamal Temsamani, Claude Laruelle
-
Patent number: 9188581Abstract: The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization.Type: GrantFiled: April 6, 2011Date of Patent: November 17, 2015Assignee: The Children's Research InstiuteInventors: Robert J. Freishtat, Eric P. Hoffman
-
Patent number: 9186320Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.Type: GrantFiled: July 30, 2011Date of Patent: November 17, 2015Assignee: MATTERN PHARMA AGInventor: Claudia Mattern
-
Patent number: 9180109Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.Type: GrantFiled: August 3, 2011Date of Patent: November 10, 2015Assignee: G. POHL-BOSKAMP GMBH & CO. KGInventor: Marianne Boskamp
-
Patent number: 9181577Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.Type: GrantFiled: November 19, 2013Date of Patent: November 10, 2015Assignee: Northwestern UniversityInventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
-
Patent number: 9168282Abstract: Disclosed is a method of treating pain. The method includes administering a lecithin as an active ingredient to a mammal to treat the pain, wherein the pain is caused by at least one of herpes zoster, post-herpetic neuralgia, and diabetic neuropathic pain. The method further includes administering at least one selected from the group consisting of vegetable gel, a vegetable resin, and a synthetic resin, wherein the vegetable gel, vegetable resin, and synthetic resin is selected from the group consisting of aloe gel; a seaweed extract selected from the group consisting of kelp extract, agar extract, and Fucoidan; and a mixture thereof.Type: GrantFiled: September 25, 2013Date of Patent: October 27, 2015Assignee: DONGKOOK PHARMACEUTICAL CO., LTD.Inventors: Jae-Hoon Jung, Hyung-Ryong Moon
-
Patent number: 9167813Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.Type: GrantFiled: January 27, 2012Date of Patent: October 27, 2015Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
-
Patent number: 9155699Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: October 17, 2013Date of Patent: October 13, 2015Assignee: Civitas Therapeutics, Inc.Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
-
Patent number: 9138407Abstract: Provided is an inhalatory pharmaceutical composition that comprises a drug, a soluble excipient and a surfactant, wherein the soluble excipient is present in an amount between 10% and less than 100% by weight; and the solid excipient forms a solid matrix in which the drug is dispersed; the weight ratio between the surfactant and drug is between 0.01 and 10; the particle size of at least 50% of the particles of the powder is below 5 ?m; the bulk density db of the powder is between 0.1 and 0.3 g/cc; the tapped density dt of the powder is between 0.15 and 0.7 g/cc and the ratio db/dt is between 0.2 and 0.65. Also provided is the method for fabricating the composition.Type: GrantFiled: October 20, 2006Date of Patent: September 22, 2015Assignee: Eratech S.R.L.Inventors: Giovanni Caponetti, Loretta Maggi, Laura Zanellotti, Cristina Veneziani
-
Patent number: 9138409Abstract: A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns.Type: GrantFiled: May 31, 2013Date of Patent: September 22, 2015Assignee: S.C. Johnson & Son, Inc.Inventors: Peter N. Nguyen, John R. Wietfeldt, Yemi S. Bullen, Francis J. Randall, Randy C. Yuhas
-
Patent number: 9125872Abstract: A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2?, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to CO2 supercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.Type: GrantFiled: October 12, 2010Date of Patent: September 8, 2015Inventor: Yosry A. Attia
-
Patent number: 9095544Abstract: The invention relates to a composition containing cetrimide suitable for cleaning inflamed or non-inflamed ears of animals, preferably of companion animals such as dogs and cats. The composition further comprises one or more carriers, such as for example wetting agents and humectants.Type: GrantFiled: December 21, 2011Date of Patent: August 4, 2015Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Joachim Karle, Reinhard Seffner, Horst Sollinger
-
Patent number: 9078923Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.Type: GrantFiled: September 11, 2014Date of Patent: July 14, 2015Assignee: GLENMARK PHARMACEUTICALS LIMITEDInventors: Ulhas Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
-
Patent number: 9072683Abstract: The present invention is directed to the use of xanthan gum, particularly heat treated xanthan gum, as a fixative in hair cosmetic compositions. Xanthan gum is advantageous in that it may be used with other hair fixatives and provides rheology modifying and other properties including excellent stiffness, gloss, dry comb, wet comb, non-flake, anti-static, feel and high humidity curl retention.Type: GrantFiled: July 18, 2002Date of Patent: July 7, 2015Assignee: AKZO NOBEL N.V.Inventors: Hongjie Cao, Gary T. Martino, Paul H. Richardson